Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$0.79 - $1.59 $74,768 - $150,483
-94,644 Reduced 67.79%
44,972 $22,000
Q2 2021

Aug 09, 2021

SELL
$3.71 - $5.13 $7,420 - $10,260
-2,000 Reduced 1.41%
139,616 $645,000
Q1 2021

May 10, 2021

SELL
$4.08 - $14.75 $134,640 - $486,750
-33,000 Reduced 18.9%
141,616 $609,000
Q4 2020

Feb 12, 2021

SELL
$11.06 - $14.01 $128,130 - $162,305
-11,585 Reduced 6.22%
174,616 $1.93 Million
Q3 2020

Nov 09, 2020

BUY
$10.26 - $14.55 $14,281 - $20,253
1,392 Added 0.75%
186,201 $2.25 Million
Q2 2020

Aug 03, 2020

BUY
$7.11 - $13.76 $1.31 Million - $2.53 Million
183,771 Added 17704.34%
184,809 $2.54 Million
Q2 2020

Jul 31, 2020

SELL
$7.11 - $13.76 $1.38 Million - $2.67 Million
-193,771 Reduced 99.47%
1,038 $2.54 Million
Q1 2020

May 06, 2020

BUY
$5.71 - $15.85 $57,100 - $158,500
10,000 Added 5.41%
194,809 $1.51 Million
Q4 2019

Jan 28, 2020

BUY
$9.6 - $17.75 $5,347 - $9,886
557 Added 0.3%
184,809 $2.82 Million
Q3 2019

Oct 15, 2019

SELL
$12.16 - $21.0 $59,340 - $102,480
-4,880 Reduced 2.58%
184,252 $2.24 Million
Q2 2019

Aug 13, 2019

SELL
$9.44 - $19.8 $18,880 - $39,600
-2,000 Reduced 1.05%
189,132 $3.75 Million
Q4 2018

Feb 11, 2019

BUY
$10.24 - $15.49 $279,633 - $423,000
27,308 Added 16.67%
191,132 $2.43 Million
Q3 2018

Oct 05, 2018

BUY
$15.53 - $19.97 $1.12 Million - $1.44 Million
71,922 Added 78.26%
163,824 $2.55 Million
Q2 2018

Aug 01, 2018

SELL
$15.88 - $19.5 $47,640 - $58,500
-3,000 Reduced 3.16%
91,902 $1.72 Million
Q1 2018

Apr 20, 2018

SELL
$13.53 - $17.47 $171,912 - $221,973
-12,706 Reduced 11.81%
94,902 $1.61 Million
Q4 2017

Jan 10, 2018

BUY
$14.41 - $19.15 $1.55 Million - $2.06 Million
107,608
107,608 $1.71 Million

Others Institutions Holding ATNX

About Athenex, Inc.


  • Ticker ATNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 156,790,000
  • Market Cap $1.57M
  • Description
  • Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...
More about ATNX
Track This Portfolio

Track Jaffetilchin Investment Partners, LLC Portfolio

Follow Jaffetilchin Investment Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jaffetilchin Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jaffetilchin Investment Partners, LLC with notifications on news.